Genmab — December 2017
-
Lidt OB’s på short i GEN. Mindst 2 ting er tankevækkende, hvis man skal finde noget positivt ift udviklingen mht GEN. Det er, trods kraftig øgning! i shorts, ikke lykkedes at sænke kursen den sidste godt og vel halve måned. Kigger man så udviklingen igennem mht Pandora for det sidste års tid, kan man se at samme AQR har haft en ringe performance, sammenlignet med andre fonde. For sent ind og for sene til at komme ud. Det kunne virke som om krudtet er tæt på at blive vådt
-
God morgen.

-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind